Beam Therapeutics Inc.
Beam Therapeutics Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on October 15, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 26.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 15, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2026 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | Trial Milestone | Phase 1/Phase 2 |
| December 30, 2027 | A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) | Trial Milestone | Phase 1/Phase 2 |
| February 15, 2028 | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease | Trial Milestone | Phase 1/Phase 2 |
| May 15, 2028 | A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) | Trial Milestone | Phase 1/Phase 2 |
Track BEAM alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BEAM in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 4, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 7, 2026 | Quarterly results filed (8-K) | Earnings | — |
| February 24, 2026 | Quarterly results filed (8-K) | Earnings | — |
| February 12, 2026 | 8-K filed: Material agreement | Corporate | — |
| February 5, 2026 | 8-K filed: Leadership change | Corporate | — |
| January 29, 2026 | This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects | Trial Milestone | Phase 1 |
| January 12, 2026 | Quarterly results filed (8-K) | Earnings | — |
| December 11, 2025 | 8-K filed: Acquisition completed | Corporate | — |
| November 4, 2025 | Quarterly results filed (8-K) | Earnings | — |
| August 5, 2025 | Quarterly results filed (8-K) | Earnings | — |
| May 6, 2025 | Quarterly results filed (8-K) | Earnings | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.